Physician

Mary M Li, M.D.

According to 2025 Medicare claims, Mary Li, M.D. (NPI: 1275503971) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hernando, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34608-1329.

Li's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 915 traditional Medicare patients, billed 388,338 HCPCS/CPT codes, and received $4,951,697 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,972 prescription claims across 321 beneficiaries totaling $3,882,432 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 50 claims. Open Payments data shows 188 records totaling $7,133. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,060,486 to $3,882,432. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $8,363 to $15,616.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,266	537,524	$5,470,018
2016	1,193	579,170	$5,981,814
2017	1,427	615,919	$6,337,587
2018	1,462	572,640	$5,823,394
2019	1,368	573,598	$6,422,194
2020	1,191	541,854	$6,963,184
2021	1,157	415,239	$5,784,597
2022	927	409,101	$4,537,619
2023	870	402,978	$4,892,585
2024	915	388,338	$4,951,697

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	281	1,649	$1,060,486
2016	274	1,686	$1,494,299
2017	261	1,585	$1,520,208
2018	268	1,541	$2,124,083
2019	262	1,408	$2,214,104
2020	244	1,493	$2,837,573
2021	261	1,531	$2,598,027
2022	289	1,718	$2,734,889
2023	285	1,983	$3,928,883
2024	321	1,972	$3,882,432

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	159	$8,366
2016	N/R	132	$7,044
2017	N/R	N/R	N/R
2018	N/R	25	$1,771
2019	N/R	17	$1,944
2020	11	15	$2,142
2021	N/R	N/R	N/R
2022	N/R	63	$2,612
2023	N/R	50	$3,494
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	349	1,018	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	421	1,050	$67
96372	Injection of drug or substance under skin or into muscle	340	1,969	$10
36415	Insertion of needle into vein for collection of blood sample	747	2,835	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	739	3,153	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	73	1,890	$1,206,313
Brukinsa	Zanubrutinib	69	2,070	$802,268
Jakafi	Ruxolitinib Phosphate	38	1,140	$534,491
Ibrance	Palbociclib	24	652	$300,755
Xtandi	Enzalutamide	12	360	$167,183

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	188	$7,133	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mary M. Li, M.D.?

Tedicare shows public-source Medicare data for Mary M. Li, M.D. (NPI 1275503971), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mary M. Li, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mary M. Li, M.D.?

Mary M. Li, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Mary M. Li, M.D. have Open Payments data?

Mary M. Li, M.D. has 188 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.